Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07288073 · ClinicalTrials.gov registry record · Phase 2
TIL Therapy in cSCC and MCC
A Phase 2 study of Skin Cancer and Merkel Cell Carcinoma, sponsored by Karam Khaddour, MD, MS.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 14
- Enrollment target
- 1
- Study location
NCT07288073: Recruiting Phase 2 study of Skin Cancer and Merkel Cell Carcinoma, sponsored by Karam Khaddour, MD, MS.
NCT07288073 is a Phase 2 study of Skin Cancer and Merkel Cell Carcinoma that is actively recruiting participants, run by Karam Khaddour, MD, MS. The registered enrollment target is 14 participants, below the 464-participant average among 40 other Skin Cancer trials with a reported enrollment target (97% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07288073, a Phase 2 study of Skin Cancer and Merkel Cell Carcinoma, is actively recruiting participants, sponsored by Karam Khaddour, MD, MS.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 14 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this research study is to test the safety and effectiveness of a tumor-infiltrating lymphocyte (TIL) cellular therapy, also called LN-145 or lifileucel, and chemotherapy in combination with Interleukin-2 (IL-2) to find out what effects, if any, the combination has on participants with Cutaneous squamous cell carcinoma (CSCC) or Merkel Cell Carcinoma (MCC) who were previously treated with immunotherapy. The names of the study interventions involved in this study are: * Tumor Infiltrating Lymphocytes (a type of cellular therapy) * Fludarabine and Cyclophosphamide (types of standard of care chemotherapy drugs) * Interleukin-2 (a type of recombinant, human glycoprotein)
Primary Outcome
Tumor-infiltrating lymphocyte (TIL) production is defined by the successful tumor harvest that leads to a manufacturing of a TIL product that contains ≥ 1 x 10\^9 cells.
Conditions Studied
Interventions
- DRUG Cyclophosphamide
- DRUG Fludarabine
- BIOLOGICAL LN-145
- BIOLOGICAL Interleukin-2
Study Locations (1)
Massachusetts
- Dana-Farber Cancer Institute - Boston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 14 participants |
| Start Date | 2026-02-10 |
| Est. Completion | 2029-06-29 |
| Phase | Phase 2 |
What NCT07288073 shows while recruiting
NCT07288073 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 14 participants, a relatively small participant target, below the 464-participant average among 40 other Skin Cancer trials with a reported enrollment target (97% lower).
The record links to 4 conditions, with Skin Cancer appearing as the primary indexed condition, and to 4 interventions - of which Cyclophosphamide is the first listed.
NCT07288073 reports a single indexed study location in Massachusetts.
Frequently Asked Questions
What is clinical trial NCT07288073 about?
NCT07288073 is a clinical study titled "TIL Therapy in cSCC and MCC". The purpose of this research study is to test the safety and effectiveness of a tumor-infiltrating lymphocyte (TIL) cellular therapy, also called LN-145 or lifileucel, and chemotherapy in combination with Interleukin-2 (IL-2) to find out what effects, if any, the combination has on participants with...
What is the current status of trial NCT07288073?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 14 participants. The study started on 2026-02-10. Estimated completion is 2029-06-29.
What conditions does trial NCT07288073 study?
This clinical trial studies the following conditions: Skin Cancer, Merkel Cell Carcinoma, Cutaneous Squamous Cell Carcinoma, Metastatic Cutaneous Squamous Cell Carcinoma.
What interventions are being tested in trial NCT07288073?
The interventions under investigation include: Cyclophosphamide (DRUG), Fludarabine (DRUG), LN-145 (BIOLOGICAL), Interleukin-2 (BIOLOGICAL).
Who is sponsoring clinical trial NCT07288073?
This trial is sponsored by Karam Khaddour, MD, MS, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07288073 being conducted?
This trial has 1 study location across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Skin Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT07288073's enrollment target sits among peer trials
14 40th of 40 the lowest of 40 other Skin Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Skin Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Cryoablation+Ipilimumab+Nivolumab in Melanoma
RECRUITING · Phase 2
-
Randomized Study of Nivolumab+Ipilimumab+/- SBRT for Metastatic Merkel Cell Carcinoma
ACTIVE NOT RECRUITING · Phase 2
-
A Study of Radiation Therapy and Cemiplimab for People With Skin Cancer
ACTIVE NOT RECRUITING · Phase 2
-
Phase II Study of Radiation Therapy and Vismodegib for Advanced Head/Neck Basal Cell Carcinoma
COMPLETED · Phase 2
-
Study of Talabostat and Cisplatin in Advanced Melanoma
COMPLETED · Phase 2
-
Phase II Trial of Allovectin-7® for Metastatic Melanoma
COMPLETED · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02523092 · 14 participants · Phase 4
Use of CXCL9 as a Biomarker of Acthar Efficacy
- NCT04263285 · 14 participants · NA
Treatment of Depression Post-SCI
- NCT04743271 · 14 participants · NA
Food and Circadian Timing
- NCT05065671 · 14 participants · Phase 1
Microbiome Derived Metabolism and Pharmacokinetics
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT06358040 · started 2026-10 · NA
Opioid Dispenser for Microdiscectomy/Laminectomy